Editas Medicine Inc. to Showcase Preclinical Gene Editing Advances at ASGCT Annual Meeting
Editas Medicine Inc., a pioneering gene editing company, is set to attend the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, LA, from May 13-17, 2025. At the event, the company plans to share in vivo preclinical data demonstrating the use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells. Additionally, Editas will present proof of concept for using in vivo CRISPR editing to upregulate a target liver protein and reduce a disease-associated biomarker.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001650664-25-000071), on May 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。